Furie et al. now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal antibody against B-lymphocyte stimulator—which both stimulates ...

In BLISS-76, 43.2% (118/273) of the high-dose belimumab group compared with 33.8% (93/275) of the placebo group achieved the primary endpoint at week 52. 7 This difference, although modest in ...

Belimumab combined with standard of care therapy is safe and effective for treating systemic lupus erythematosus. Belimumab combined with standard of care (SOC) therapy shows promising efficacy ...